Article: Conjugation of latent membrane protein (LMP)-2 epitope to gold nanoparticles as highly immunogenic multiple antigenic peptides for induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses in vitro

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleConjugation of latent membrane protein (LMP)-2 epitope to gold nanoparticles as highly immunogenic multiple antigenic peptides for induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses in vitro
AuthorsCheung, WH2 4
Chan, VSF1 2
Pang, HW4
Wong, MK4
Guo, ZH3
Tam, PKH2
Che, CM4
Lin, CL1 2
Yu, WY4 5
Issue Date2009
PublisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/bc
CitationBioconjugate Chemistry, 2009, v. 20 n. 1, p. 24-31 [How to Cite?]
DOI: http://dx.doi.org/10.1021/bc800167q
AbstractNasopharyngeal carcinoma is a neoplasm with a high incidence in Southeast Asia, and it is strongly associated with Epstein-Barr virus (EBV) activation involving the expression of a weakly immunogenic protein, namely, latent membrane protein (LMP)-2. Previous immunological studies already identified the human leukocyte antigen (HLA)-All restricted peptide epitope (SSCSSCPLSK) in the LMP-2 antigen. In this work, we prepared gold nanoparticle (AuNP)-peptide conjugate 1 by treating the nanoparticles with the Af-cysteinated LMP-2 epitope. The AuNP-peptide conjugates have been characterized by TEM (15-24 nm in diameter) and UV-vis spectroscopy (surface plasmon resonance absorption band at λmax = 520 nm). In the presence of a CALNN capping peptide, the AuNP-peptide conjugates are stable in solution without aggregation at room temperature for at least 48 h. By ELIspot studies, AuNP-peptide conjugate 1 was found to elicit a significantly stronger INF-γ response [number of spot forming cells (SPC) = 727 ± 198] from peripheral blood mononuclear cells of healthy HLA-A11 donors when compared to that induced by the unconjugated LMP-2 peptides (SFC = 73 ± 28). Further studies showed that dendritic cells treated with conjugate 1 can effect CD8+ T-cell activation leading to epitope-specific cytotoxic T lymphocyte killing responses in vitro. © 2009 American Chemical Society.
ISSN1043-1802
2011 Impact Factor: 4.93
2011 SCImago Journal Rankings: 0.484
DOIhttp://dx.doi.org/10.1021/bc800167q
ReferencesReferences in Scopus
GrantsDevelopment and clinical evaluation of peptide vaccines for immunotherapy of Epstein-Barr virus-positive nasopharyngeal carcinoma
Development and clinical evaluation of peptide vaccines for immunotherapy of Epstein-Barr virus-positive nasopharyngeal carcinoma
Institute of molecular technology for drug discovery and synthesis
Development of DNA and viral vector vaccines against Epstein-Barr virus-positive nasopharyngeal carcinoma
Discovery and clinical evaluation of novel immunogenic peptides for immunotherapy of nasopharyngeal carcinoma
DC Field
Value
dc.contributor.authorCheung, WH
dc.contributor.authorChan, VSF
dc.contributor.authorPang, HW
dc.contributor.authorWong, MK
dc.contributor.authorGuo, ZH
dc.contributor.authorTam, PKH
dc.contributor.authorChe, CM
dc.contributor.authorLin, CL
dc.contributor.authorYu, WY
dc.date.accessioned2011-03-28T09:25:21Z
dc.date.available2011-03-28T09:25:21Z
dc.date.issued2009
dc.description.abstractNasopharyngeal carcinoma is a neoplasm with a high incidence in Southeast Asia, and it is strongly associated with Epstein-Barr virus (EBV) activation involving the expression of a weakly immunogenic protein, namely, latent membrane protein (LMP)-2. Previous immunological studies already identified the human leukocyte antigen (HLA)-All restricted peptide epitope (SSCSSCPLSK) in the LMP-2 antigen. In this work, we prepared gold nanoparticle (AuNP)-peptide conjugate 1 by treating the nanoparticles with the Af-cysteinated LMP-2 epitope. The AuNP-peptide conjugates have been characterized by TEM (15-24 nm in diameter) and UV-vis spectroscopy (surface plasmon resonance absorption band at λmax = 520 nm). In the presence of a CALNN capping peptide, the AuNP-peptide conjugates are stable in solution without aggregation at room temperature for at least 48 h. By ELIspot studies, AuNP-peptide conjugate 1 was found to elicit a significantly stronger INF-γ response [number of spot forming cells (SPC) = 727 ± 198] from peripheral blood mononuclear cells of healthy HLA-A11 donors when compared to that induced by the unconjugated LMP-2 peptides (SFC = 73 ± 28). Further studies showed that dendritic cells treated with conjugate 1 can effect CD8+ T-cell activation leading to epitope-specific cytotoxic T lymphocyte killing responses in vitro. © 2009 American Chemical Society.
dc.description.grantDevelopment and clinical evaluation of peptide vaccines for immunotherapy of Epstein-Barr virus-positive nasopharyngeal carcinoma
dc.description.grantDevelopment and clinical evaluation of peptide vaccines for immunotherapy of Epstein-Barr virus-positive nasopharyngeal carcinoma
dc.description.grantInstitute of molecular technology for drug discovery and synthesis
dc.description.grantDevelopment of DNA and viral vector vaccines against Epstein-Barr virus-positive nasopharyngeal carcinoma
dc.description.grantDiscovery and clinical evaluation of novel immunogenic peptides for immunotherapy of nasopharyngeal carcinoma
dc.description.grantcode37101
dc.description.grantcode9758
dc.description.grantcode8708
dc.description.grantcode18600
dc.description.grantcode8015
dc.description.naturelink_to_subscribed_fulltext
dc.identifier.citationBioconjugate Chemistry, 2009, v. 20 n. 1, p. 24-31 [How to Cite?]
DOI: http://dx.doi.org/10.1021/bc800167q
dc.identifier.doihttp://dx.doi.org/10.1021/bc800167q
dc.identifier.epage31
dc.identifier.hkuros155039
dc.identifier.isiWOS:000262659700005
Funding AgencyGrant Number
Innovation and Technology Commission (HKSAR)ITS/211/01
University of Hong Kong
UGC20600433
NSFC/RGCN_HKU 721/04
RGCCERGHKU 7444/03M
Areas of Excellence SchemeAoE/P-10/01
Funding Information:

We acknowledge the financial support of the Innovation and Technology Fund (ITS/211/01) administered by the Innovation and Technology Commission (HKSAR), The University of Hong Kong (University Development Fund and UGC matching grant No. 20600433), NSFC/RGC (N_HKU 721/04), RGCCERG (HKU 7444/03M), and the Areas of Excellence Scheme (AoE/P-10/01) established under the University Grants Council, HKSAR.

dc.identifier.issn1043-1802
2011 Impact Factor: 4.93
2011 SCImago Journal Rankings: 0.484
dc.identifier.issue1
dc.identifier.pmid19102689
dc.identifier.scopuseid_2-s2.0-61849144830
dc.identifier.spage24
dc.identifier.urihttp://hdl.handle.net/10722/132491
dc.identifier.volume20
dc.languageeng
dc.publisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/bc
dc.publisher.placeUnited States
dc.relation.ispartofBioconjugate Chemistry
dc.relation.referencesReferences in Scopus
dc.subject.meshAntigens, Viral - immunology
dc.subject.meshCD8-Positive T-Lymphocytes - immunology
dc.subject.meshCytotoxicity, Immunologic
dc.subject.meshGold
dc.subject.meshHerpesvirus 4, Human - immunology
dc.subject.meshHumans
dc.subject.meshLymphocyte Activation - immunology
dc.subject.meshMetal Nanoparticles - chemistry
dc.subject.meshT-Lymphocytes, Cytotoxic - immunology
dc.subject.meshViral Matrix Proteins - chemistry - immunology
dc.titleConjugation of latent membrane protein (LMP)-2 epitope to gold nanoparticles as highly immunogenic multiple antigenic peptides for induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses in vitro
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Institute of Molecular Technology for Drug Discovery and Synthesis, Hong Kong
  3. Imperial College London
  4. Hong Kong Polytechnic University
  5. Hong Kong University of Science and Technology